What MiMedx Group (MDXG) Said on Its Q3 Earnings Call
MiMedx Group (MDXG) reported Q3 earnings with gross profit of $50M, down from $95M YoY, and a GAAP net loss of $9M. Wound care volume rose 20% YoY, but margins declined due to pricing and product mix. The company expects 2027 conditions to persist and anticipates modest EBITDA growth in Q4. MiMedx is acquiring Sanara MedTech, facing FTC review, aiming for $400M revenue and 20% EBITDA margin post-merger. Legal and product updates include a $25M settlement and progress on 510(k) submissions.
How this was made

The 30-second read
Why it matters
The earnings release combines a loss with operational improvements and a regulatory hurdle, creating mixed signals for traders.
Market read
Earnings miss and FTC delay are likely to weigh on MDXG stock today, while margin recovery offers a potential upside catalyst later.
What to watch
The upcoming Medicare fee schedule release in November could stabilize pricing, and the $300M term loan provides financing flexibility.
Background
MiMedx discussed wound care volume growth, margin trends, and legal updates alongside its Sanara acquisition progress.
Ticker impact
MiMedx Group reported Q3 GAAP net loss of $9M, adjusted EBITDA turned positive, and disclosed FTC second request delaying its Sanara MedTech acquisition.
likely pressure as the market prices in the loss and regulatory delay
The loss and FTC request are fresh primary disclosures that can move the stock immediately; margin improvement is modest and may not offset the negative news.
Market effects
Wound care and surgical device sectors may see heightened scrutiny of reimbursement and M&A timelines.
U.S. biotech investors may reassess exposure to companies with pending FTC reviews.
Limited to investors tracking U.S. biotech earnings and M&A pipelines.
Counterpoint
Margin improvements and potential cost synergies from the Sanara deal could support a longer‑term rebound despite the short‑term loss.
Key entities
- companyMiMedx Group
Biotech firm focused on wound care and surgical products.
- companySanara MedTech
Target of MiMedx's pending acquisition.
- regulatorFederal Trade Commission
Issued a second request extending the HSR waiting period for the acquisition.


